文献速递母胎医学产科

低风险与高风险妊娠中游离DNA筛查21、18、13三体的遗传学确认研究

Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation.
PubMed 文献 · Am J Obstet Gynecol · 2022-01-25

这项多中心前瞻性观察研究在6国21个中心纳入20,194例孕妇,采用单核苷酸多态性游离DNA筛查21、18、13三体,并经产前或新生儿DNA样本确认遗传学结局。低风险组筛查阳性率低于高风险组(0.27% vs 2.2%),两组敏感性和特异性相似;21三体阳性预测值低风险组85.7%、高风险组97.5%。无结果者三体检出率高于首次采血有结果者(2.8% vs 0.7%)。

要点

  • 低风险组21三体阳性预测值为85.7%,三种常见三体合计为74.3%。
  • 低风险组较高风险组筛查阳性率更低(0.27% vs 2.2%),敏感性与特异性相似。
  • 获得无结果者三体风险升高(2.8% vs 0.7%),需进一步检查。

核心结论

  • 在低风险孕妇中,基于单核苷酸多态性的游离DNA筛查对21、18、13三体具有高敏感性和高特异性,21三体阳性预测值为85.7%,三种常见三体合计为74.3%。
  • 获得无结果的患者染色体非整倍体风险升高,需要进一步检查。

研究设计与样本

  • 多中心前瞻性观察研究,在6个国家的21个中心开展。
  • 纳入接受基于单核苷酸多态性的游离DNA筛查21、18、13三体的孕妇,共20,194例,中位孕周12.6周(四分位距11.6-13.9)。
  • 遗传学确认来自产前或新生儿DNA样本,共确认17,851例(88.4%),其中低风险13,043例(73.1%)、高风险4808例(26.9%)。
  • 同时评估了一种对妊娠结局设盲的更新版游离DNA算法。

主要发现

  • 共诊断133例三体(21三体100例、18三体18例、13三体15例)。
  • 低风险组筛查阳性率低于高风险组(0.27% vs 2.2%;P<.0001)。
  • 低风险组与高风险组21三体阳性预测值分别为85.7%与97.5%(P=.058),18三体分别为50.0%与81.3%(P=.283),13三体分别为62.5%与83.3%(P=.58)。
  • 首次采血后602例(3.4%)无结果,计入第二次采血后287例(1.61%)无结果。
  • 287例无结果者三体率高于首次采血即有结果者(2.8% vs 0.7%;P=.001)。

临床怎么用

  • 作者结论指出,低风险孕妇可选择基于单核苷酸多态性的游离DNA筛查,其对21三体阳性预测值为85.7%、对三种常见三体合计为74.3%。
  • 作者结论指出,获得无结果者非整倍体风险升高,需要进一步检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cell-free DNA noninvasive prenatal screening for trisomies 21, 18, and 13 has been rapidly adopted into clinical practice. However, previous studies are limited by a lack of follow-up genetic testing to confirm the outcomes and accurately assess test performance, particularly in women at a low risk for aneuploidy. OBJECTIVE: To measure and compare the performance of cell-free DNA screening for trisomies 21, 18, and 13 between women at a low and high risk for aneuploidy in a large, prospective cohort with genetic confirmation of results STUDY DESIGN: This was a multicenter prospective observational study at 21 centers in 6 countries. Women who had single-nucleotide-polymorphism-based cell-free DNA screening for trisomies 21, 18, and 13 were enrolled. Genetic confirmation was obtained from prenatal or newborn DNA samples. The test performance and test failure (no-call) rates were assessed for the cohort, and women with low and high previous risks for aneuploidy were compared. An updated cell-free DNA algorithm blinded to the pregnancy outcome was also assessed. RESULTS: A total of 20,194 women were enrolled at a median gestational age of 12.6 weeks (interquartile range, 11.6-13.9). The genetic outcomes were confirmed in 17,851 cases (88.4%): 13,043 (73.1%) low-risk and 4808 (26.9%) high-risk cases for aneuploidy. Overall, 133 trisomies were diagnosed (100 trisomy 21; 18 trisomy 18; 15 trisomy 13). The cell-free DNA screen positive rate was lower in the low-risk vs the high-risk group (0.27% vs 2.2%; P<.0001). The sensitivity and specificity were similar between the groups. The positive predictive value for the low- and high-risk groups was 85.7% vs 97.5%; P=.058 for trisomy 21; 50.0% vs 81.3%; P=.283 for trisomy 18; and 62.5% vs 83.3; P=.58 for trisomy 13, respectively. Overall, 602 (3.4%) patients had no-call result after the first draw and 287 (1.61%) after including cases with a second draw. The trisomy rate was higher in the 287 cases with no-call results than patients with a result on a first draw (2.8% vs 0.7%; P=.001). The updated algorithm showed similar sensitivity and specificity to the study algorithm with a lower no-call rate. CONCLUSION: In women at a low risk for aneuploidy, single-nucleotide-polymorphism-based cell-free DNA has high sensitivity and specificity, positive predictive value of 85.7% for trisomy 21 and 74.3% for the 3 common trisomies. Patients who receive a no-call result are at an increased risk of aneuploidy and require additional investigation.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Dar P, Jacobsson B, MacPherson C, et al. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. Am J Obstet Gynecol. 2022. PMID: 35085538. doi:10.1016/j.ajog.2022.01.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。